Latest Information Update: 22 Mar 2010
At a glance
- Originator Bayer Schering Pharma
- Class Contrast media; Lanthanoid series elements
- Mechanism of Action Magnetic resonance imaging enhancers
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Vascular disorders
Most Recent Events
- 02 Aug 2001 Phase-I clinical trials for Vascular disorders (diagnosis) in Germany (unspecified route)